Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 2, 2020

Hologic receives US contract to scale-up Covid-19 test production

Hologic has secured a $119m contract from the US Government to scale-up its production capacity for molecular tests for Covid-19.

Hologic has secured a $119m contract from the US Government to scale-up its production capacity for molecular tests for Covid-19.

According to the contract, the company will provide 13 million Covid-19 molecular tests a month to the US by January 2022.

The tests run on the fully automated Panther Fusion and Panther systems, which deliver initial results in approximately three hours and are capable of processing over 1,000 tests in 24 hours.

The US Food and Drug Administration (FDA) granted emergency use authorisation (EUA) for Hologic’s Panther Fusion SARS-CoV-2 Assay and Aptima SARS-CoV-2 Assay in March and May respectively.

Hologic Diagnostic Solutions Division president Kevin Thornal said: “Hologic has already made significant investments in our test production capacity, which have resulted in our contributing tens of millions of Covid tests to the US supply.

“Our manufacturing teams continue to innovate to increase our contribution and we are very pleased to partner with the federal government to further our ability to meet the ongoing public health need.”

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The Panther molecular diagnostics system is a sample-to-result platform that can be used in low, medium, or high-throughput laboratories.

Incorporated with small footprint, adaptable workflow options, and consolidated testing menu, the platform merges women’s health, sexually transmitted infections, and viral testing, which can be carried out simultaneously.

Moreover, patient samples can be loaded onto the Panther system as they reach the lab, a capability known as random access that improves efficiency and workflow.

With high throughput and quick turnaround time, the instrument helps to deliver sample results faster.

The Panther Fusion system combines polymerase chain reaction (PCR) chemistry and provides an expanded in vitro diagnostics menu with an open access functionality that helps to run laboratory-developed tests.

The systems offer 16 FDA-cleared assays and 20 CE-marked assays that can detect over 20 pathogens.

As many as 2,000 of these systems have been installed in clinical diagnostic laboratories worldwide with all 50 US states equipped with the systems.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU